NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain
Key Highlights
- ➤OneRF first patient remained pain-free after minimally invasive trigeminal nerve ablation
- ➤OneRF procedure can take as little as 20 to 30 minutes
- ➤OneRF tests multiple nerve locations through one probe insertion
- ➤NeuroOne expanding direct sales and distribution to accelerate commercialization
- ➤NeuroOne’s OneRF Trigeminal Nerve Ablation System is FDA 510(k)-cleared
Expert Statements
Michael Staudt, Neurosurgeon at University Hospitals
“Unlike conventional radiofrequency ablation probes that require repeated repositioning to identify and treat different nerve locations, NeuroOne’s OneRF Trigeminal Nerve Ablation System enables physicians to test multiple nerve locations through a single probe insertion, offering patients a more comfortable procedure compared to known commercially available trigeminal nerve radiofrequency (RF) ablation systems.”
Dave Rosa, Chief Executive Officer of NeuroOne
“This is one of many patient success stories we have seen with OneRF for trigeminal neuralgia, and it is incredibly rewarding to see the profound impact our technology can have on patients suffering from this devastating condition.”
Dave Rosa, Chief Executive Officer of NeuroOne
“Stories like this reinforce our sense of urgency and responsibility to make this technology available to more patients. We are actively expanding our direct sales and distribution efforts to accelerate commercialization and broaden access to our OneRF Trigeminal Nerve Ablation System across the country.”
NeuroOne’s FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia
EDEN PRAIRIE, Minn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today highlighted a feature article published in the New York Post showcasing the successful treatment of a patient* suffering from trigeminal neuralgia, a debilitating neurological condition, using the Company’s FDA 510(k)-cleared OneRF(®) Trigeminal Nerve Ablation System.
Get started
Create a free account to read the full story.